• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,886.91 -416.72
( -0.54%)
Global Indices
Nasdaq
49,198.35 -53.37
(-0.11%)
Dow Jones
7,195.79 9.71
(0.14%)
Hang Seng
59,839.06 -698.30
(-1.15%)
Nikkei 225
10,332.91 11.82
(0.11%)
Forex
USD-INR
93.91 -0.14
(-0.15%)
EUR-INR
110.02 0.03
(0.03%)
GBP-INR
127.00 0.16
(0.13%)
JPY-INR
0.59 0.00
(-0.03%)

EQUITY - MARKET SCREENER

Shukra Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
524632
INE551C01044
1.5028279
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
46.45
1362.68
EPS(TTM)
Face Value()
Div & Yield %
0.67
1
0.03
 

tata steel ltd
Karur Vysya Bank reappoints B Ramesh Babu as MD & CEO
Jan 27,2026
His current term is scheduled to end on July 28, 2026.

The board has recommended his reappointment for a third term of two years, effective 29 July, 2026. The appointment will be subject to the approval of the Reserve Bank of India (RBI) and the shareholders of the bank.

Karur Vysya Bank provides services such as personal, corporate, and agricultural banking and services to NRIs and SMBs.

The bank reported a 39.1% jump in standalone net profit to Rs 689.96 crore on an 11.8% increase in total income to Rs 3,303.13 crore in Q3 FY26 over Q3 FY25.

Shares of Karur Vysya Bank rose 0.66% to end at Rs 265.35 on the BSE.